Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma Patients

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Neuroblastoma (NB) lacks reliable prognostic biomarkers for effective risk stratification and treatment.
• The beta-3 adrenergic receptor (β3-AR) is implicated in tumor progression and metastasis in various cancers.

Purpose of the Study:

• To evaluate the expression of β3-AR in different tissues of neuroblastoma patients.
• To determine the correlation of β3-AR expression with patient survival and clinical characteristics.
• To assess the potential of β3-AR as a prognostic biomarker for NB.

Main Methods:

• β3-AR expression was analyzed in bone marrow, peripheral blood, circulating tumor cells, disseminated tumor cells, and tumor biopsies using flow cytometry and immunofluorescence.
• Statistical analyses included Receiver Operating Characteristic (ROC) curves, Fisher's exact test, and Kaplan-Meier curves.
• A cohort of 45 NB patients was studied.

Main Results:

• β3-AR expression was significantly higher in peripheral blood of NB patients compared to healthy controls at diagnosis and follow-up.
• High β3-AR expression in disseminated tumor cells at diagnosis was linked to shorter event-free survival (p=0.0005).
• Elevated β3-AR in bone marrow at diagnosis predicted worse overall survival (p=0.0076), and increased PB β3-AR at follow-up correlated with shorter overall survival (p=0.0015).

Conclusions:

• β3-AR is a promising prognostic biomarker for neuroblastoma.
• β3-AR expression levels can aid in risk stratification and monitoring disease progression in NB patients.
• Further validation of β3-AR as a prognostic tool in NB is warranted.